Pyrimethamine-sulfadoxine Treatment of Congenital Toxoplasmosis: Follow-up of 78 Cases Between 1980 and 1997

REFERENCES

• Bougnoux ME, Hubert B. Toxoplasmose congénitale. Bilan de la prévention primaire en France. B E H 1990; 4: 13–4.
   Google Scholar
• Remington JS, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant, 4th edn. Philadelphia: WB Saunders, 1995: 140–267.
   Google Scholar
• Desmonts G, Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N Engl J Med 1974; 290: 1110–6.
   PubMed Web of Science ®Google Scholar
• Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980; 66: 767–74.
   PubMed Web of Science ®Google Scholar
• Koppe JG, Loewer-Sieger DH, De Roever-Bonnet H. Results of 20 years follow up of congenital toxoplasmosis. Lancet 1986; 1: 254–6.
   PubMed Web of Science ®Google Scholar
• Guerina NG, Hsu HW, Meissner HC, Maguire J, Lynfield R, Stechenberg B, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 26: 1858–63, 1994.
   Web of Science ®Google Scholar
• Lappalainen M, Koskiniemi M, Hiilesmaa V, Ammala P, Teramo K, Koskela P, et al. Outcome of children after maternal primary Toxoplasma infection during pregnancy with emphasis on avidity of specific IgG. Pediatr Infect Dis J 1995; 14: 354–61.
   PubMed Web of Science ®Google Scholar
• Guerina NG. Congenital infection with Toxoplasma gondii. Pediatr Ann 1994; 23: 138–51.
   PubMed Web of Science ®Google Scholar
• Stray-Pedersen B. Treatment of toxoplasmosis in the pregnant mother and newborn child. Scand J Infect Dis 1992; 84: 23–31.
   Google Scholar
• Garin JP, Mojon M, Piens MA, Chevalier-Nuttall I. Surveillance et traitement de la toxoplasmose chez la femme enceinte, le foetus et le nouveau-né. Pediatrie 1989; 44: 705–12.
   Google Scholar
• Couvreur J, Thulliez P, Daffos F, Aufrant C, Bompard Y, Gesquiere A, Desmonts G. In utero treatment of toxoplasmic fetopathy with the combination Pyrimethamine–Sulfadiazine. Fetal Diagn Ther 1993; 8: 45–50.
   PubMed Web of Science ®Google Scholar
• Hohlfeld P, Daffos F, Thulliez P, Aufrant C, Couvreur J, MacAleese J, Descombey D, Forestier F. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989; 115: 765–9.
   PubMed Web of Science ®Google Scholar
• Berrebi A, Kobuch WE, Bessieres MH. Termination of pregnancy for maternal toxoplasmosis. Lancet 1994; 334: 36–9.
   Google Scholar
• Pinon JM, Poirriez J, Leroux B, Thoannes D, Dupouy D, Gari M, Jezierski J, Quereux C. Diagnostic précoce, surveillance et bilan thérapeutique de la toxoplasmose congénitale. Indications des profils immunologiques comparés ELIFA. Rev Int Pediatr 1986; 157: 11–6.
   Google Scholar
• Pinon JM, Chemla C, Villena I, Foudrinier F, Aubert D, Toubas D, et al. Early neonatal diagnosis of congenital toxoplasmosis: value of comparative Enzyme-Linked-Immunofiltration Assay immunological profiles and anti-Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for postnatal therapeutic strategies. J Clin Microbiol 1996; 34: 579–83.
   PubMed Web of Science ®Google Scholar
• Hezard N, Marx-Chemla C, Foudrinier F, Villena I, Quereux C, Leroux B, et al. Prenatal diagnosis of congenital toxoplasmosis in 261 pregnancies. Prenat Diagn 1997; 17 (11): 1047–54.
   PubMed Web of Science ®Google Scholar
• Marx C, Foudrinier F, Trenque T, Fay R, Dupouy D, Leroux B, et al. Toxoplasmose congénitale et dosage de la pyriméthamine. L. Eurobiologiste 1993; 27: 369–74.
   Google Scholar
• Dorangeon PH, Fay R, Marx-Chemla C, Leroux B, Harika G, Dupouy D, et al. Passage transplacentaire de l’association pyriméthamine–sulfadoxine lors du traitement anténatal de la toxoplasmose congénitale. Presse Med 1990; 19 (44): 2036.
   Google Scholar
• Daffos F, Forestier F, Cappella-Pavlovsky M, Thulliez P, Aufrant C, Valenti D, Cox WL. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med 1988; 318: 271–5.
   Google Scholar
• Meenken C, Assies J, van Nieuwenhuizen O, Holwerda-van der Maat W, Schooneveld M, Delleman W, et al. Long term ocular and neurological involvement in severe congenital toxoplasmosis. Br J Ophtalmol 1995; 79: 581–4.
   Google Scholar
• Couvreur J, Desmonts G, Aron-Rosa D. Le pronostic oculaire de la toxoplasmose congénitale: rô le du traitement. Ann Pediatr 1984; 31: 855–8.
   Google Scholar
• McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago collaborative treatment trial. Clin Infect Dis 1994; 18: 38–72.
   PubMed Web of Science ®Google Scholar
• Roizen N, Swisher CN, Stein MA, Hopkins J, Boyer KM, Holfels E, et al. Neurologic and development outcome in treated congenital toxoplasmosis. Pediatrics 1995; 95: 11–20.
   PubMed Web of Science ®Google Scholar
• Peyron F, Wallon M, Bernardoux C. Long-term follow-up of patients with congenital ocular toxoplasmosis. N Engl J Med 1996; 334: 993–4.
   Google Scholar
• De Vroede M, Dodion J, De Meuter F, Piepsz A, Ver-ougstraete C. Congenital toxoplasmosis: late appearance of retinal lesions after treatment. Acta Pediatr Scand 1979; 68: 761–2.
   Google Scholar
• Nussenblatt RB, Mital KK, Fuhrman S, Sharma SD, Palestine AG. Lymphocyte proliferative responses of patients with ocular toxoplasmosis to parasite and retinal antigens. Am J Ophtalmol 1989; 107: 632–41.
   Google Scholar
• Wyler DJ, Blackman HJ, Lunde MN. Cellular hypersensitivity to toxoplasmal and retinal antigens in patients with toxoplasmal retinochoroiditis. Am J Trop Med Hyg 1980; 29: 1180–6.
   Google Scholar
• Wilson C. Treatment of congenital toxoplasmosis. Letter to Editor. Pediatr Infect Dis J 1990; 9: 682–3.
   PubMed Web of Science ®Google Scholar
• Fricker-Hidalgo H, Pelloux H, Bost M, Goullier-Fleuret A, Ambroise-Thomas P. Toxoplasmose congénitale: Apport du suivi biologique postnatal. Presse Méd 25: 1868–72, 1996.
   PubMed Web of Science ®Google Scholar
• Couvreur J. Toxoplasmose congénitale. Prise en charge et devenir. Med Mal Infect 1993; 23: 176–82.
   Web of Science ®Google Scholar
• McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob Agents and Chemother 1992; 36: 1040–8.
   PubMed Web of Science ®Google Scholar
• Huskinson-Mark J, Araujo FG, Remington JS. Evalution of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis 1991; 164: 170–7.
   Google Scholar
• Derouin F. New pathogens and mode of action of azithromycin Toxoplasma gondii. Path Biol 1995; 43: 561–4.
   PubMedGoogle Scholar
• Maisonneuve H, Faber C, Piens MA, Garin JP. Congenital toxoplasmosis. Tolerance to the pyrimethamine–sulfadoxine combination 24 cases. Presse Med 1984; 13: 859–62.
   PubMed Web of Science ®Google Scholar
• Desmonts G, Daffos F, Forestier F, Cappella-Pavlovsky M, Thulliez P, Chartier M. Prenatal diagnosis of congenital toxoplasmosis. Lancet 1985; 1: 500–4.
   Google Scholar
• Matsui D. Prevention, diagnosis, and treatment of fetal toxoplasmosis. Fetal Drug Ther 1994; 21: 675–89.
   Google Scholar
• Dorangeon PH, Marx-Chemla C, Quereux C, Fay R, Leroux B, Dupouy D, Choisy H, Pinon JM, Wahl P. Les risques de l’association Pyrimethamine–Sulfadoxine dans le traitement anténatal de la toxoplasmose. J Gynecol Obstet Biol Reprod 1992; 21: 549–56.
   PubMedGoogle Scholar
• Pyrimethamine combinations in pregnancy. Editorial. Lancet ii: 1005–7, 1983.
   Google Scholar
• Barbosa J, Ferreira I. Sufadoxine–Pyrimethamine (Fansidar) in pregnant women with Toxoplasma antibody titers. Curr Chemother 1978; 1: 134–5.
   Google Scholar